-
EXCLUSIVE: The Psychedelics Debate Is 'Raging' As Filament Debuts Ayahuasca Pill
Friday, December 16, 2022 - 11:15am | 957Read More...Part two of a three-part series. Previous story: Standardized Ayahuasca Pill Is Officially Here, Feast Yourself With The Exclusive Details & Insights When it comes to the ayahuasca pill, Filament Health (OTCMTKS: FLHLF) CEO Ben Lightburn says the product won’t just be for the...
-
Beyond Magic Mushrooms: Positive Clinical Trial For Treatment-Resistant Depression & Alcoholism
Wednesday, November 16, 2022 - 2:53pm | 405Read More...Private clinical-stage psychedelics biotech Beckley Psytech announced it has successfully completed a Phase 1 clinical study on BPL-003, its patent-protected, synthetic intranasal formulation of 5-MeO-DMT under development for Treatment-Resistant Depression (TRD) and Alcohol Use Disorder (AUD.)...
-
Rani Therapeutics Shares Climb On Positive Results From Initial-Stage Bone Disease Study
Wednesday, August 10, 2022 - 4:51pm | 247Read More...Rani Therapeutics (NASDAQ: RANI) announced positive topline results from the single-ascending dose (SAD) portion of its Phase 1 clinical study of its lead asset RT-102 for the potential treatment of osteoporosis. RT-102 is a RaniPill capsule containing a proprietary formulation of human parathyroid...
-
Oppenheimer Adjusts FRX Estimates Following CLDA Acquisition Announcement
Wednesday, February 23, 2011 - 9:52am | 191Read More...On 2/22, Forest Laboratories, Inc. (NYSE: FRX) announced an agreement to acquire Clinical Data, Inc. (NASDAQ: CLDA) with the transaction expected complete ~2Q11. “FRX will pay $30.00/sh plus up to $6.00/sh related to Viibryd commercial milestones,” Oppenheimer writes. “At ~2.0x our Viibryd peak...
-
Piper Jaffray Raises PT On Clinical Data
Monday, January 24, 2011 - 7:59am | 28Read More...Piper Jaffray has raised the price target on Clinical Data, Inc. (NASDAQ: CLDA) from $23 to $31 and maintains its Overweight rating.
-
Piper Jaffray Reiterates Overweight on Clinical Data (CLDA)
Tuesday, November 30, 2010 - 9:42am | 114Read More...Piper Jaffray reiterates its Overweight rating on Clinical Data (NASDAQ: CLDA) following CLDA's sale of its cardiac diagnostic testing business. In a note to clients, Piper Jaffray writes, "Clinical Data is selling its cardiac diagnostic testing business, Familion, to Transgenomic for $15.4 million...
